Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
Submitted by
admin
on March 20, 2018 - 3:34pm
Source:
CP Wire
News Tags:
Inovio
China
ApolloBio
VGX-3100
DNAi-based therapeutics
HPV
Headline:
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
Do Not Allow Advertisers to Use My Personal information
